DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera, Medical Writer, Auckland, New Zealand. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. January 2018.
Guselkumab is a biological treatment indicated for moderate-to-severe psoriasis.
The US Food and Drug Administration (FDA) has approved guselkumab (Tremfya™, Janssen Biotech, PA, USA) for the treatment of adults living with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Guselkumab is the first and only approved biological therapy that selectively blocks only interleukin 23 (IL-23), a cytokine that plays a key role in plaque psoriasis.
Applications seeking approval of guselkumab in the European Union, Japan, and other countries are currently under review.
The safety and effectiveness of guselkumab in paediatric patients < 18 years of age have not been evaluated.
Clinical studies with guselkumab did not include sufficient numbers of patients aged 65 years to determine whether they respond differently from younger subjects.
No trials have been conducted to assess the effect of hepatic or renal impairment on the pharmacokinetics of guselkumab.
The most common adverse reactions (≥ 1% of patients) reported include:
Guselkumab should not be used in patients that:
Guselkumab is promising for plaque psoriasis in Phase III studies.
See the DermNet NZ bookstore.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.